Skip Nav Destination
Drug Discovery
Emerging Drugs and Targets for Multiple Sclerosis
Edited by
Ana Martinez
Ana Martinez
Centro de Investigaciones Biologicas-CSIC, Spain
Search for other works by this author on:
Hardback ISBN:
978-1-78801-450-2
PDF ISBN:
978-1-78801-607-0
EPUB ISBN:
978-1-78801-806-7
Special Collection:
2019 ebook collection
Series:
Drug Discovery Series
No. of Pages:
333
Published online:
18 Jun 2019
Published in print:
28 Jun 2019
About this book
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials. Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.
Emerging Drugs and Targets for Multiple Sclerosis, The Royal Society of Chemistry, 2019.
Download citation file:
Digital access
$220.00
Print format
Emerging Drugs and Targets for Multiple Sclerosis
$220.00
Table of contents
-
CHAPTER 1: Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needsp1-32ByIrene Moreno-Torres;Irene Moreno-TorresNeuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research InstituteManuel de Falla 128222 MadridSpain[email protected]Autonomous University of MadridMadridSpainSearch for other works by this author on:Julia Sabín-Muñoz;Julia Sabín-MuñozPuerta de Hierro University Hospital, Neuroimmunology UnitManuel de Falla 128222 MadridSpainSearch for other works by this author on:Antonio García-MerinoAntonio García-MerinoNeuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research InstituteManuel de Falla 128222 MadridSpain[email protected]Autonomous University of MadridMadridSpainPuerta de Hierro University Hospital, Neuroimmunology UnitManuel de Falla 128222 MadridSpainSearch for other works by this author on:
-
CHAPTER 2: Genetics of Multiple Sclerosisp33-54ByDavid A. Hafler;David A. HaflerDepartment of Immunobiology, Yale School of MedicineNew HavenCTUSABroad Institute of MIT and HarvardCambridgeMAUSASearch for other works by this author on:Erin E. LongbrakeErin E. LongbrakeCenter for Neuroepidemiology and Clinical Neurological Research, Yale School of MedicineNew HavenCTUSASearch for other works by this author on:
-
CHAPTER 3: Biomarkers for Multiple Sclerosisp55-75ByAmalia Tejeda Velarde;Amalia Tejeda VelardeInstituto Ramón y Cajal para la Investigación Sanitaria (IRYCIS)SpainRed Española de Esclerosis Múltiple (REEM)SpainSearch for other works by this author on:Silvia Medina Heras;Silvia Medina HerasInstituto Ramón y Cajal para la Investigación Sanitaria (IRYCIS)SpainRed Española de Esclerosis Múltiple (REEM)SpainSearch for other works by this author on:Luisa María Villar GuimeransLuisa María Villar GuimeransInstituto Ramón y Cajal para la Investigación Sanitaria (IRYCIS)SpainRed Española de Esclerosis Múltiple (REEM)SpainSearch for other works by this author on:
-
CHAPTER 4: Optical Coherence Tomography in Multiple Sclerosisp76-87ByRicardo Alonso;Ricardo AlonsoClinical of Multiple Sclerosis, Neurology Department, Hospital Jose María Ramos Mejía, Urquiza 609Buenos AiresArgentina[email protected]Clinic of Multiple Sclerosis and Neuroimmunology, Neurology Department, University Hospital Sanatorio GuemesBuenos AiresArgentinaSearch for other works by this author on:Leila CohenLeila CohenClinical of Multiple Sclerosis, Neurology Department, Hospital Jose María Ramos Mejía, Urquiza 609Buenos AiresArgentina[email protected]Neurophthalmology Section, Neurology Department, Hospital Jose María Ramos MejíaBuenos AiresArgentinaSearch for other works by this author on:
-
CHAPTER 5: Experimental In Vivo Models for Drug Discovery in Multiple Sclerosisp88-110ByCarmen GuazaCarmen GuazaSearch for other works by this author on:
-
CHAPTER 6: Progressive Multiple Sclerosis: Drug Discoveryp111-133ByEbtesam Alshehri;Ebtesam AlshehriMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland ClinicClevelandOHUSA[email protected]Search for other works by this author on:Jeffery A. CohenJeffery A. CohenMellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland ClinicClevelandOHUSA[email protected]Search for other works by this author on:
-
CHAPTER 7: B Cell-based Therapies for Multiple Sclerosisp134-169ByMichael Osherov;Michael OsherovDepartment of Neurology, Barzilai University Medical Center2 Hahistadrut St.Ashkelon 7830604Israel[email protected][email protected]Search for other works by this author on:Ron MiloRon MiloDepartment of Neurology, Barzilai University Medical Center2 Hahistadrut St.Ashkelon 7830604Israel[email protected][email protected]Faculty of Health Sciences, Ben-Gurion University of the NegevBeer-ShevaIsraelSearch for other works by this author on:
-
CHAPTER 8: Protein Kinase Inhibitors for the Treatment of Multiple Sclerosisp170-196ByCarmen GilCarmen GilSearch for other works by this author on:
-
CHAPTER 9: Emerging Drugs and Targets for Remyelination in Multiple Sclerosisp197-221ByLaura J. Wagstaff;Laura J. WagstaffMRC Centre for Regenerative Medicine and MS Society, Edinburgh Centre for MS Research, University of Edinburgh5 Little France DriveEdinburgh EH16 4UUUK[email protected]Search for other works by this author on:Anna WilliamsAnna WilliamsMRC Centre for Regenerative Medicine and MS Society, Edinburgh Centre for MS Research, University of Edinburgh5 Little France DriveEdinburgh EH16 4UUUK[email protected]Search for other works by this author on:
-
CHAPTER 10: Regulation of Oligodendrocyte Differentiation: New Targets for Drug Discovery in Remyelinationp222-240ByFernando de Castro;Fernando de CastroGrupo de Neurobiología del Desarrollo-GNDe, Instituto Cajal, Spanish Research Council/CSIC-Consejo Superior de Investigaciones CientíficasMadridSpain[email protected]Search for other works by this author on:Fernando Josa-PradoFernando Josa-PradoGrupo de Neurobiología del Desarrollo-GNDe, Instituto Cajal, Spanish Research Council/CSIC-Consejo Superior de Investigaciones CientíficasMadridSpain[email protected]Universidad Alfonso X El Sabio, Avenida de la Universidad1;28691Villanueva de la CañadaMadridSpainSearch for other works by this author on:
-
CHAPTER 11: Cannabinoids as a Therapeutic Approach in Multiple Sclerosisp241-263ByGareth Pryce;Gareth PryceCentre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of LondonLondonE1 2ATUnited Kingdom[email protected]Search for other works by this author on:David BakerDavid BakerCentre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of LondonLondonE1 2ATUnited Kingdom[email protected]Search for other works by this author on:
-
CHAPTER 12: Sigma Receptors as New Target for Multiple Sclerosisp264-284BySimona CollinaSimona CollinaSearch for other works by this author on:
-
CHAPTER 13: Non-coding RNA and Multiple Sclerosis: New Targets for Drug Discoveryp285-301ByDavid OtaeguiDavid OtaeguiSearch for other works by this author on:
-
CHAPTER 14: Diet, Gut Microbiome and Multiple Sclerosisp302-326ByJavier Ochoa-RepárazJavier Ochoa-RepárazSearch for other works by this author on:
Spotlight
Advertisement
Advertisement
